KEI Staff's blog

More notes on the India EU FTA (BTIA)

Earlier KEI published sections of the the EU India Negotiating FTA/BTIA negotiating text dealing with enforcement, along with some commentary on Article 17-31:

On March 28, 2013, KEI obtained another document with Article 1-5,7-8,10-33 of the negotiating next. The new text is available at

Krista Cox will be providing her impressions here:

Here are KEI's quick reactions to the text.

Among the provisions in the TRIPS which protect consumers are Article 7, 8 and 40.

Hague Conference again seeks global norms on Recognition and Enforcement of foreign judgments

On Wednesday, January 23rd, 2013, the Department of State will convene a meeting to discuss a proposal by the Hague Conference on Private International Law ("Hague Conference") to developing a new "instrument" on the recognition and enforcement of judgments, including "new jurisdictional filters."

KEI letter to Steve Ricchetti, asking recusal in matters that involve former clients

On March 12, 2012, Tedmund Wan posted a note on Joe Biden's appointment of Steve Ricchetti, exploring potential conflicts of interest with the clients in a lobbying firm that he ran. On March 29, 2012, KEI formally asked Ricchetti to recuse himself in matters concerning his former clients. The letter follows.


29 March 2012

Steve Ricchetti
Counselor to Vice President Joe Biden
The White House

Who is Sally Susman, and why does she want poor people to pay higher prices for medicines?

Sally Susman of Pfizer leads the most lethal lobbying effort on drug patents and prices. She's also a big Obama campaign fundraiser.

For several years, Pfizer has been considered a hardliner among big pharma companies on international negotiations over intellectual property rights and drug pricing. This has not changed despite the company having had three CEOs in the past five years.

February 22 noon Washington, DC meeting to discuss international negotiations on copyright (With international call-in)

On Wednesday February 22, 2012, from 12:30pm to 2:30pm, KEI will host a roundtable discussion on international copyright negotiations. The location of the meeting will be 1621 Connecticut Ave, NW, Suite 500, Washington, DC 20009. There will be an opportunity to participate by telephone, via toll free calls in many countries. (To register or for details on call-in, email If you want to try to join by skype, we will do our best.)

The topics to be discussed are the following International copyright negotiations:

KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)

KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).

bayer_logo.gifThe Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.

NGO views on the Africa IP Summit

Sangeeta Shashikant from TWN recently collected and published several NGO statements on the Africa IP Summit, in the TWO Info Service on Intellectual Property Issues (Feb12/03), which included a link also to a letter to WIPO signed by more than 100 NGOs.

Seven public health groups write to oppose the "Research Works Act"

On February 8, 2012, seven public health organisations submitted a letter to Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform and the other thirty-nine members of this committee opposing H.R. 3699, the "Research Works Act." This bill, originally introduced on December 16, 2011 by Rep. Issa and Rep. Maloney (D-NY) would prohibit federal agencies from conditioning its federal grants on recipients making its published research results available to the public.

FDA New drug approvals for 2011, through June 6

This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.

6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.

  • NMEs were 10.7 percent of all approvals.
  • The NME priority NDAs were 4 percent of FDA approvals.

Confirmation that Obama Administration was "lone hold out" for releasing bracketed ACTA text to the public in Summer of 2010.

On July 1, 2010, William Yue, the Senior Counsel, Office of the Chief Counsel for International Commerce at the US Department of Commerce, wrote to Joel Blank and John Cobau about the ACTA negotiations. John Cobau was the Chief Counsel for International Commerce at the U.S. Department of Commerce, and Joel Blank was International Attorney-Advisor at US Department of Commerce.

A redacted version of this email was the only document released to KEI as part of a larger FOIA request concerning the Department of Commerce role in the ACTA negotiations. A copy is available here:

Six NGOs present recommendations for Moscow WHO forum on non-communicable diseases

Six NGOs, including Knowledge Ecology International (KEI), Medecins Sans Frontieres (MSF), Oxfam, Third World Network (TWN), Universities Allied for Essential Medicines (UAEM), and Young Professionals Chronic Disease Network (YP-CDN), recently submitted recommendations to Member States to control non-communicable diseases (NCDs) in low- and middle-income countries in advance of the Moscow Ministerial conference.

A PDF of the joint statement with logos of the groups is available here:

MEPs Marietje Schaake and Christian Engstrom submit question on appointment of Maria Martin-Prat to EU copyright post

70879-christian-engstrom-parti-pirate-suedois_250x350.jpg marietje-1.jpg On April 1, 2011, Marietje SCHAAKE and Christian ENGSTRÖM submitted a parliamentary question on the appointment of Maria Martin-Part as the new head of unit for copy

The production of generic drugs in India: A new trade agreement with the EU would hinder access to drugs in developing countries

On March 22, 2011, the British Medical Journal (BMJ) published the following guest editorial about the EU/India Free Trade Agreement negotiations.

UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation

The following groups and individuals have written to Anand Grover, the Special Rapporteur for the United Nations on the right of everyone to the enjoyment of the highest attainable standard of health, to lodge a complaint about the Trans Pacific Partnership (TPP). The TPP is a regional free trade agreement being negotiated by the governments of Brunei, Chile, New Zealand, Singapore, Australia, Malaysia, Peru, Vietnam and the United States.

The complete Feb 10, 2011 text of the US proposal for the TPP IPR chapter

KEI has obtained the February 10, 2011 US government draft of the intellectual property chapter of the Trans-Pacific Partnership Agreement (TPP).

Syndicate content